|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
TRIANGULAR MOVING AVERAGE
Trading: BUY @ $1.805
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Mesoblast (ASX:MSB) currently has a confirmed uptrend. Recent trading has caused the TMA 15 day average to exceed the closing price confirming the short term trend following indicator. Currently, the return on TMA15 is 1.1%.
A triangular moving average can be calculated using various input data such as prices volume or another technical indicator.
Calculation: Triangular Moving Average (TMA):
1) SMA: n period sum / n;
2) TMA = (n SMA period sum) / N;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|EML Emerchants||4.35||13.6||7,106,370||5.7||BULLISH CROSSOVER|
|APX Appen||22.66||5.9||1,026,466||4.2||BULLISH CROSSOVER|
|DTL Data#3||3.43||5.2||1,162,137||0.9||BULLISH CROSSOVER|
|KAR Karoon Gas Australia||1.1||3.8||5,014,070||4.3||BULLISH CROSSOVER|
|PGC Paragon Care||0.43||3.6||423,426||0.5||BULLISH CROSSOVER|
|SMX Sms Management & Technology||0.3||3.4||1,266||1.4||BULLISH CROSSOVER|
|DNK Danakali||0.65||3.2||124,521||2.8||BULLISH CROSSOVER|
|UOS United Overseas Australia||0.83||2.5||2,369||1||BULLISH CROSSOVER|
|MVF Monash IVF||1.03||2.5||1,948,555||0.9||BULLISH CROSSOVER|
|MXI Maxitra Industries||0.23||2.3||109,500||1.4||BULLISH CROSSOVER|